Receipt of RhD‐positive whole blood for life‐threatening bleeding in female children: A survey in alloimmunized mothers regarding minimum acceptable survival benefit relative to risk of maternal alloimmunization to anti‐D

Abstract

AbstractBackgroundLow‐titer group O whole blood (LTOWB) for treatment of hemorrhagic shock sometimes necessitates transfusion of RhD‐positive units due to short supply of RhD‐negative LTOWB. Practitioners must choose between using RhD‐positive LTOWB when RhD‐negative is unavailable against the risk to a female of childbearing potential of becoming RhD‐alloimmunized, risking hemolytic disease of the fetus and newborn (HDFN) in future children, or using component therapy with RhD‐negative red cells. This survey asked females with a history of red blood cell (RBC) alloimmunization about their risk tolerance of RhD alloimmunization compared to the potential for improved survival following transfusion of RhD‐positive blood for an injured RhD negative female child.Study Design and MethodsA survey was administered to RBC alloimmunized mothers. Respondents were eligible if they were living in the United States with at least one red cell antibody known to cause HDFN and if they had at least one RBC alloimmunized pregnancy.ResultsResponses from 107 RBC alloimmmunized females were analyzed. There were 32/107 (30%) with a history of severe HDFN; 12/107 (11%) had a history of fetal or neonatal loss due to HDFN. The median (interquartile range) absolute improvement in survival at which the respondents would accept RhD‐positive transfusions for a female child was 4% (1%–14%). This was not different between females with and without a history of severe or fatal HDFN (p = .08 and 0.38, respectively).ConclusionAlloimmunized mothers would accept the risk of D‐alloimmunization in a RhD‐negative female child for improved survival in cases of life‐threatening bleeding.